Protium klugii

Protium klugii · Accepted scientific name

Scientific literature: Very Sparse (1 studies) · ★☆☆☆☆

Protium klugii is a botanical species of interest within the study of natural bioactive compounds. Researchers have specifically focused their attention on the chemical properties found within the plant's leaf. Scientific investigations have revealed that extracts from these leaves exhibit significant cytotoxic activities. This potential for inhibiting cell growth makes the plant a candidate for further pharmacological exploration. Understanding these mechanisms is essential for identifying new therapeutic agents derived from natural sources.

Quick facts
Synonyms
Bursera Klugii
Common names
Not available
Family
Burseraceae
Distribution
Southern America
Plant Parts
Leaf

Classification

Common Names

Protium klugii is a remarkable species that is recognized by several distinct common names depending on the region. It is widely known as Copal Negro, a title that highlights its unique characteristics. In other areas, people frequently refer to the plant as Cumalillo. It is also affectionately called Incienso, reflecting its aromatic qualities. These various names all point to the diverse ways this plant is perceived and used by different communities.

Sources: Catalogue of Life (COL)

Synonyms

Protium klugii is a botanical name that is frequently encountered in taxonomic studies of tropical flora. It is important to note that this species is also widely recognized by its synonym, Bursera klugii. Because of this dual nomenclature, researchers may occasionally find the plant listed under either designation in scientific literature. Understanding these overlapping identities is essential for anyone studying the evolutionary lineage of these plants. Ultimately, recognizing both names ensures accuracy when documenting the diverse relationships within the plant kingdom.

Sources: The World Checklist of Vascular Plants (WCVP)

Taxonomy

Protium klugii is a distinct biological entity belonging to the vast kingdom Plantae. Within this expansive group, it is specifically classified under the class Equisetopsida. This plant further refines its lineage as a member of the order Sapindales. It belongs to the family Burseraceae, which helps scientists understand its unique evolutionary traits. Ultimately, it is defined by its placement within the specialized genus Protium.

Rank Classification
Kingdom Plantae
Phylum Streptophyta
Class Equisetopsida
Subclass Magnoliidae
Order Sapindales
Family Burseraceae
Genus Protium

Sources: The World Checklist of Vascular Plants (WCVP)

Distribution

Geographic Regions

Protium klugii is a notable plant species primarily distributed throughout the diverse landscapes of Southern America. Its presence is particularly strong across Brazil, stretching from the central regions into the north. The species also extends its reach into Western South America, where it flourishes in the unique environments of Colombia. Additionally, it can be found inhabiting various territories within Peru, contributing to its wide regional footprint. This broad distribution highlights the plant's ability to adapt to the different ecological zones found across the continent.

Sources: The World Checklist of Vascular Plants (WCVP)

Identification

Morphology

Protium klugii is a self-supporting tree that establishes a sturdy presence within its ecosystem. This botanical species typically reaches a maximum height of 20 meters as it matures. Its distinct growth form allows it to thrive and contribute to the structural complexity of its natural habitat.

Sources: Global Inventory of Floras and Traits (GIFT)

Biological Activities

Protium klugii, also known as Bursera klugii, has demonstrated significant cytotoxic activity within various biological test systems. Research into the ethanol extract of its leaves revealed a crude chloroform-soluble fraction capable of targeting specific cancer cells. Specifically, this plant shows measurable activity against the P-388 lymphocytic leukemia cell line and the human epidermoid carcinoma of the nasopharynx. The observed cytotoxic effects are primarily attributed to two specific constituents known as sapelins A and B. These findings highlight the potential pharmacological importance of the chemical compounds isolated from this species.

Compounds

Protium klugii, as identified in recent chemical studies, is a source of specific bioactive compounds. Research indicates that this plant species contains the particular constituents known as sapelins A and B. These substances were isolated from the chloroform-soluble fractions of ethanol extracts derived from the plant's leaves. Testing has demonstrated that sapelins A play a significant role in the cytotoxic activity observed against various cell lines. Such findings highlight the potential medicinal importance of these chemical relationships within the species.

Conditions

Protium klugii exhibits significant medicinal potential through its ability to treat P-388 lymphocytic leukemia (3PS). This plant also demonstrates effectiveness in treating human epidermoid carcinoma of the nasopharynx (9KB). These therapeutic properties are linked to the cytotoxic activity found within its chemical constituents. Specifically, the interaction with these two distinct test systems highlights its diverse anticancer capabilities. Such biological activities underscore the plant's importance in studying potential treatments for these specific malignancies.

Preparations

Parts used

Protium klugii is a species that is often studied alongside its botanical relatives within the Burseraceae family. Research into related species like Bursera klugii has highlighted the significant chemical potential found within their natural components. Specifically, the leaves of these plants have been processed to create ethanol extracts for medicinal testing. These extracts can yield bioactive constituents, such as sapelins A and B, which demonstrate activity against various cancer cell lines. Understanding these plant parts and their chemical properties is essential for advancing pharmacological discovery.